Put Options

16 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$9.04 - $11.75 $485,447 - $630,975
-53,700 Reduced 60.54%
35,000 $347,000
Q1 2024

May 15, 2024

SELL
$11.43 - $14.24 $1.46 Million - $1.82 Million
-128,100 Reduced 59.09%
88,700 $1.04 Million
Q4 2023

Feb 14, 2024

BUY
$9.97 - $14.52 $416,746 - $606,936
41,800 Added 23.89%
216,800 $3.08 Million
Q3 2023

Nov 14, 2023

BUY
$11.78 - $13.86 $1.12 Million - $1.32 Million
95,000 Added 118.75%
175,000 $2.13 Million
Q2 2023

Aug 14, 2023

SELL
$10.72 - $13.3 $643,200 - $798,000
-60,000 Reduced 42.86%
80,000 $1 Million
Q1 2023

May 15, 2023

BUY
$10.91 - $13.54 $436,400 - $541,600
40,000 Added 40.0%
140,000 $1.55 Million
Q4 2022

Feb 14, 2023

BUY
$9.89 - $12.7 $989,000 - $1.27 Million
100,000 New
100,000 $1.22 Million
Q2 2022

Aug 15, 2022

BUY
$6.23 - $11.12 $311,500 - $556,000
50,000 Added 100.0%
100,000 $1.07 Million
Q2 2021

Aug 16, 2021

SELL
$8.71 - $10.72 $1.74 Million - $2.14 Million
-200,000 Reduced 80.0%
50,000 $482,000
Q1 2021

May 17, 2021

SELL
$9.2 - $23.86 $3.31 Million - $8.59 Million
-360,000 Reduced 59.02%
250,000 $2.47 Million
Q4 2020

Feb 16, 2021

BUY
$13.47 - $24.89 $6.2 Million - $11.4 Million
460,000 Added 306.67%
610,000 $14.1 Million
Q3 2020

Nov 16, 2020

BUY
$12.89 - $15.89 $1.16 Million - $1.43 Million
90,000 Added 150.0%
150,000 $2.12 Million
Q2 2020

Aug 14, 2020

BUY
$8.86 - $15.69 $177,200 - $313,800
20,000 Added 50.0%
60,000 $905,000
Q1 2020

May 15, 2020

BUY
$6.63 - $11.16 $265,200 - $446,400
40,000 New
40,000 $370,000
Q4 2019

Feb 13, 2020

SELL
$7.48 - $10.75 $149,600 - $215,000
-20,000 Closed
0 $0
Q2 2019

Aug 13, 2019

BUY
$10.96 - $14.4 $219,200 - $288,000
20,000 New
20,000 $249,000

Others Institutions Holding FOLD

About AMICUS THERAPEUTICS, INC.


  • Ticker FOLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 280,497,984
  • Market Cap $2.53B
  • Description
  • Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...
More about FOLD
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.